Evidence map›Paper›PMID 31713848›Full record

ArticleBritish journal of pharmacology2020

NOP receptor antagonism reduces alcohol drinking in male and female rats through mechanisms involving the central amygdala and ventral tegmental area.

Anna Maria Borruto, Yannick Fotio, Serena Stopponi, Gloria Brunori, Michele Petrella, Francesca Felicia Caputi, Patrizia Romualdi, Sanzio Candeletti, Rajesh Narendran, Linda M Rorick-Kehn and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Rostromedial tegmental nucleus nociceptin/orphanin FQ (N/OFQ) signaling regulates anxiety- and depression-like behaviors in alcohol withdrawn rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Anna Maria BorrutoSchool of Pharmacy, Pharmacology Unit, University of Camerino, Italy.ORCID 0000-0002-0953-8865
Yannick FotioSchool of Pharmacy, Pharmacology Unit, University of Camerino, Italy.
Serena StopponiSchool of Pharmacy, Pharmacology Unit, University of Camerino, Italy.
Gloria BrunoriSchool of Pharmacy, Pharmacology Unit, University of Camerino, Italy.
Michele PetrellaSchool of Pharmacy, Pharmacology Unit, University of Camerino, Italy.
Francesca Felicia CaputiDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Patrizia RomualdiDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Sanzio CandelettiDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Bologna, Italy.ORCID 0000-0001-8905-7393
Rajesh NarendranDepartment of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Linda M Rorick-KehnLilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, USA.
Massimo UbaldiSchool of Pharmacy, Pharmacology Unit, University of Camerino, Italy.
Friedbert WeissDepartment of Molecular and Cellular Neuroscience, The Scripps Research Institute, La Jolla, California, USA.
Roberto CiccocioppoSchool of Pharmacy, Pharmacology Unit, University of Camerino, Italy.ORCID 0000-0003-3126-9240
Università di Camerino · ITUniversity of Bologna · ITEli Lilly (United States) · USScripps Research Institute · USUniversity of Pittsburgh · US

Funding

The Nociceptin ORL1 System: Treatment Target for RelapseR01AA014351 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI Friedbert Weiss · 2004 to 2026
$7.3M
NIAAA NIH HHS R01 AA014351
6 · The paper itself

Abstract

background and purposeNociceptin/orphanin FQ (N/OFQ) peptide and its cognate receptor (NOP) are widely expressed in mesolimbic brain regions where they play an important role in modulating reward and motivation. Early evidence suggested that NOP receptor activation attenuates the rewarding effects of drugs of abuse, including alcohol. However, emerging data indicate that NOP receptor blockade also effectively attenuates alcohol drinking and relapse. To advance our understanding of the role of the N/OFQ-NOP receptor system in alcohol abuse, we examined the effect of NOP receptor blockade on voluntary alcohol drinking at the neurocircuitry level. EXPERIMENTAL APPROACH: Using male and female genetically selected alcohol-preferring Marchigian Sardinian (msP) rats, we initially evaluated the effects of the selective NOP receptor antagonist LY2817412 (3, 10, and 30 mg·kg KEY

resultsPeripheral LY2817412 administration dose-dependently and selectively reduced voluntary alcohol intake in male and female msP rats. Central injections of LY2817412 markedly attenuated voluntary alcohol intake in both sexes following administration in the CeA and VTA but not in the NAc. CONCLUSION AND IMPLICATIONS: The present results revealed that the CeA and VTA are neuroanatomical substrates that mediate the effects of NOP receptor antagonism on alcohol consumption. Overall, our findings support the potential of NOP receptor antagonism as a treatment strategy to attenuate alcohol use and addiction.

Indexed as

Central Amygdaloid NucleusPharmaceutical PreparationsAlcohol DrinkingAnimalsFemaleMaleOpioid PeptidesRatsReceptors, OpioidVentral Tegmental AreaOpioid PeptidesPharmaceutical PreparationsReceptors, Opioid

Identifiers

PMID31713848
PMCPMC7060370
OpenAlexW2988967107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.